Hottest Sectors Unite, PMCB Operating in
both MJ and Biotech with Huge Upside as
they Target Cancer and Diabetes Treatment
Hi and good afternoon,
Tonight its time to focus on what could be one of the
hottest Biotech plays of 2015. Yes, thats a bold statement
but were talking about a very bold company
operates in the TWO hottest, most active sectors on the small
markets: Cannabis and Biotech!
If youve been with us for a while or even just since the
start of 2015, you know that some of our biggest runners of all
time have come from one of these two industries
Biotech. PharmaCyte Biotech (PMCB) has operations in both:
As just a small market company PMCB received orphan drug
designation from the US FDA for the Companys pancreatic
cancer treatment! PMCB now has exclusive rights to a technology
that could redefine the way we treat pancreatic cancer.
PharmaCyte Biotech is developing treatments for cancer based upon
chemical constituents of the Cannabis plant, known as
Since the middle of last year, as you can see in the chart, PMCB
provided many trade opportunities as it rose and fell
consistently, many times over many months, from the .30 range to
the .15 range.
Just recently it slipped a bit lower
it closed today at
.11. This could be a remarkable bottom floor situation.
The Company is in the process of beginning a preclinical study.
This could be happening ANYTIME NOW. Once up and running we could
see plenty of reason for PMCB followers to get excited
and a swing back up from this level would mean enormous
PMCB is also a better class of company, a best of the best
on the small markets, if you will
so lets get to it:
was formerly known as Nuvilex. The company underwent a name
change in January of this year to become PharmaCyte Biotech
Before we even get into the operations (and they are impressive)
I want to show you something
something you can use in this
situation and others to help determine long-term trends.
What Im going to show you here is a quarter-by-quarter
breakdown of highs and lows for the past 8 quarters (two years):
First Quarter - High 07c Low 05c
Second Quarter - High 07c Low 05c
Third Quarter - High 04c Low 03c
Fourth Quarter - High 10c Low 03c
First Quarter - High 17c Low 10c
Second Quarter - High 17c Low 11c
Third Quarter - High 20c Low 09c
Fourth Quarter - High 51c Low 27c
What you can see here is a general trend. In 2013 when the
company was finding its way, there was some volatility at low
levels with the high just reaching into double-digits at 10
2014 it continued this general trend of moving upward over time,
yet in the interim there was still significant volatility.
Were talking constant doubles or more... quarter after
Then it hits .51
amazing. Someone who had it from just .03,
a few quarters prior, could have seen a run of 1600pct.
And you ask why I love small market Biotechs? THIS IS WHY! They
have a massive following and can be extremely volatile.
Just learn the pattern. What is the trend?
Now here it is in 2015 and it closed today at .11, not too far
off of its low of .095
so what do you think will happen
Now lets take a closer look at PharmaCyte
PMCB is a clinical stage biotechnology company focused on
developing and preparing to commercialize treatments for cancer
and diabetes based upon a proprietary cellulose-based live cell
encapsulation technology known as Cell-in-a-Box.
As we touched on earlier, the Company changed its name from
Nuvilex to PharmaCyte Biotech last month. This name change is
part of the process to operate as a pure Biotech firm leveraging
its Cell-in-a-Box technology.
This unique and patented technology will be used as a platform
upon which treatments are being built for several types
of cancer, including advanced inoperable pancreatic cancer, and
PMCB is working towards improving the quality of life for
patients with advanced
pancreatic cancer and on treatments for
other types of solid cancerous tumors.
In fact, just a couple months back, PMCB announced that
the U.S. FDA has granted them Orphan Drug Designation for its
pancreatic cancer treatment.
PMCBs treatment for pancreatic cancer involves low doses of
the well-known anticancer prodrug ifosfamide, together with
encapsulated live cells, which convert ifosfamide into its active
or cancer-killing form. These capsules are placed as
close to the tumor as possible to enable the delivery of the
highest levels of the cancer-killing drug directly at the source
of the cancer. This "targeted
chemotherapy" has proven remarkably effective in past
addition, PharmaCyte Biotech is developing treatments for cancer based upon chemical
constituents of the Cannabis plant, known as cannabinoids.
As part of their research into cannabinoids, the Company
has been examining ways to exploit the benefits of Cell-in-a-Box
technology in optimizing the anticancer effectiveness of
cannabinoids, while minimizing or outright eliminating
the debilitating side effects usually associated with cancer
PMCB plans to use this breakthrough technology to develop
approaches to fighting
deadly cancers, such as those of the pancreas, brain and breast,
which affect hundreds of thousands of individuals worldwide each
One thing of which this Company is particularly focused on is
Diabetes. Type One and Two diabetes are both wreaking havoc
across the world and in the U.S. alone more than 29.1Mln
people are affected.
The market for the treatments PMCB are working on are absolutely
- A report from Transparency Market Research states that
the global market for biotechnology, is projected
to grow at an average
annual growth rate of CAGR 11.6% from 2012 to 2017
and reach a value
worth 414.5Bln Dlrs by the end of 2017.
- It is estimated that by 2017 the drugs treatment
market for diabetes will be worth 55.3Bln Dlrs.
- The antidiabetic medicines industry generated 35.6Bln
Dlrs in 2012, and its revenues will show strong growth to
- Worldwide there are about 350Mln people who have been
diagnosed with diabetes and
countless Mlns who remain undiagnosed. In the U.S.
alone, the annual
diabetes costs are approaching 300Bln Dlrs.
- In a recent poll from Gallup, in 2013 a record number of
Americans were in favor of medical MJ (58%).
- Researchers found that more than 2.34Bln
Dlrs of Med-MJ were to be sold in 2014.
- According to Greenwave Advisors, if all 50 states
legalize MJ and the federal government followed suit, the
combined sales for Medical and Recreational MJ would
reach higher than 35Bln USD by 2020.
Right now biotech and cannabis are two of the hottest sectors
and PMCB is involved with both of them.
Not only is this Company operating in the hottest markets out
there, but have also made some enormous developments in recent
months which have placed them on the cutting-edge of these
Now lets take a look at some the groundbreaking
developments made by PMCB over the last year or so:
- Receiving orphan drug designation from the US
FDA for the Companys pancreatic cancer treatment,
with applications filed with the EMA and the TGA for the
same status in Europe and Australia.
- Development of a clinical protocol for a planned Phase 2b
clinical trial with the goal of initiating the clinical
trial in 2015.
- A preclinical study being completed evaluating the
effectiveness of their pancreatic cancer treatment.
- The establishment of a worldwide Diabetes Consortium with
a number of research agreements put into place with major
universities and institutions that will permit the
development of a breakthrough treatment for insulin
dependent diabetes that combines Cell-in-a-Box with
- Progression at the University of Northern Colorado in the
pursuit of treatments for brain and other forms of
difficult to treat cancer that will combine cannabinoid
and related compounds with the Cell-in-a-Box technology.
"With exciting developments on the horizon for 2015,
our work to develop treatments for both cancer and diabetes will
move forward under our new name because it speaks to what we
actually do here at PharmaCyte Biotech," concluded Mr.
Waggoner, CEO of PharmaCyte Biotech.
Further information on recent developments can be found here:
Shareholder Update on Cancer and Diabetes Programs
There was also an Analyst Report issued by BrokerBank Securities
earlier this month. Access the analyst report here:
PharmaCyte Biotech Analyst Report
the size of this market and a disruptive technology PMCB stands a
chance to make a great leap in 2015, and the recent developments
have shown a great upside potential.
Management believes its objective is to become an
PMCB may have one of the most exclusive Biotech technologies that
weve seen in the small markets for quite some time.
Also consider that PMCB is not only a biotech but that it is also
developing MJ based treatments making it a part of the two
hottest sectors on the small markets right now MJ and Biotech.
Currently at just .11 there could
be significant upside potential.
So get started on researching this exciting young pharma beast
it could get very
exciting very quickly.
Remember, we always encourage you to do further research. Never
take our word for it, read our disclaimer to see why, and of
course always consult a professional.
Just because a situation looks great things can still go wrong
and often do. The past is not always a good indication of what
the future will bring. Be smart and protect yourself.
Enjoy your afternoon,